Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.43 |
| ▸ | SMO | Q99835 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.42 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19001112 | 0.89 | OGA (0.54) | MAPTALDH1A1KDM4ESMN1; SMN2GAA | |
| SCHEMBL2733659 | 0.87 | MAPT (0.59) | MAPTALDH1A1KDM4ESMN1; SMN2GAA | |
| SCHEMBL19001143 | 0.86 | HSD11B1 (0.39) | MAPTALDH1A1KDM4ESMN1; SMN2GAA | |
| SCHEMBL2733014 | 0.85 | SMN1; SMN2 (0.50) | MAPTALDH1A1KDM4ESMN1; SMN2GAA | |
| SCHEMBL13248473 | 0.84 | KDM4E (0.51) | MAPTALDH1A1KDM4ESMN1; SMN2GAA | |
| SCHEMBL9906416 | 0.84 | TRPV1 (0.52) | MAPTALDH1A1KDM4ESMN1; SMN2GAA | |
| SCHEMBL10331339 | 0.83 | TRPV1 (0.51) | MAPTALDH1A1KDM4EGAAPOLB | |
| SCHEMBL13757422 | 0.81 | MAPT (0.60) | MAPTALDH1A1KDM4ESMN1; SMN2POLB | |
| SCHEMBL21419372 | 0.81 | HRH3 (0.53) | MAPTALDH1A1KDM4ESMN1; SMN2GAA | |
| SCHEMBL19001113 | 0.81 | MAPT (0.35) | MAPTALDH1A1KDM4ESMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-10-06 | — | — | US | disclosed |
| US-20220152215-A1 | Immunoconjugates Targeting CEA | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220143012-A1 | Macromolecule-Supported TLR Agonists | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200347061-A1 | CLASS OF AMINO-SUBSTITUTED NITROGEN-CONTAINING FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-10807971-B2 | Pyrrolidinone compounds | ELI LILLY AND COMPANY (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200140556-A1 | Methods and Compositions for Dectin-2 Stimulation and Cancer Immunotherapy | HOWARD HUGHES MEDICAL INSTITUTE | 2020-05-07 | — | — | US | disclosed |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2020-04-30 | — | — | US | disclosed |
| US-20190345144-A1 | PYRROLIDINONE COMPOUNDS | ELI LILLY AND COMPANY | 2019-11-14 | — | — | US | disclosed |
| US-9452997-B2 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2016-09-27 | — | — | US | disclosed |
| US-9452997-B2 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2016-09-27 | — | — | US | disclosed |
| US-20140343075-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-20140343075-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8822476-B2 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8822476-B2 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-20120059016-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347061-A1 | CLASS OF AMINO-SUBSTITUTED NITROGEN-CONTAINING FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | FGFR4, FGFR3, FGFR1 | MAPT 4112/4885ALDH1A1 1188/4885KDM4E 729/4885 |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | MAPT 3617/4885ALDH1A1 2833/4885KDM4E 3116/4885 |
| US-20140343075-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, PLA2G2E | MAPT 3630/4885ALDH1A1 2635/4885KDM4E 1526/4885 |
| US-20190345144-A1 | PYRROLIDINONE COMPOUNDS | NPY4R, NPY2R, NPY5R | MAPT 4361/4885ALDH1A1 1579/4885KDM4E 177/4885 |
| US-10807971-B2 | Pyrrolidinone compounds | NPY4R, NPY2R, NPY5R | MAPT 4361/4885ALDH1A1 1579/4885KDM4E 177/4885 |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | CRBN, ARAF, VHL | MAPT 3617/4885ALDH1A1 2833/4885KDM4E 3116/4885 |
| US-20200140556-A1 | Methods and Compositions for Dectin-2 Stimulation and Cancer Immunotherapy | TLR2, TLR8, TLR3 | MAPT 2548/4885ALDH1A1 4668/4885KDM4E 3877/4885 |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | EGFR, ERBB2, ERBB3 | MAPT 2834/4885ALDH1A1 3472/4885KDM4E 4494/4885 |
| US-20120059016-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, PLA2G2E | MAPT 3630/4885ALDH1A1 2635/4885KDM4E 1526/4885 |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | MAPT 3617/4885ALDH1A1 2833/4885KDM4E 3116/4885 |
| US-20220152215-A1 | Immunoconjugates Targeting CEA | CD47, FCGR3B, FCGR1A | MAPT 3434/4885ALDH1A1 1242/4885KDM4E 3982/4885 |
| US-20220143012-A1 | Macromolecule-Supported TLR Agonists | TLR8, TLR7, TLR9 | MAPT 3090/4885ALDH1A1 2748/4885KDM4E 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.